CoChat
Sign Up
Cited by 102Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Agmatine rescues autistic behaviors in the valproic acid-induced animal model of autism

Kim, Ji-Woon, Seung, Hana, Kim, Ki Chan, Gonzales, Edson Luck T., Oh, Hyun Ah, Yang, Sung Min, Ko, Mee Jung, Han, Seol-Heui, Banerjee, Sourav, Shin, Chan Young·2017·Neuropharmacology
DOI 10.1016/j.neuropharm.2016.09.014
Open this paper in CoChat — free account

Abstract

Autism spectrum disorder (ASD) is an immensely challenging developmental disorder characterized primarily by two core behavioral symptoms of social communication deficits and restricted/repetitive behaviors. Investigating the etiological process and identifying an appropriate therapeutic target remain as formidable challenges to overcome ASD due to numerous risk factors and complex symptoms associated with the disorder. Among the various mechanisms that contribute to ASD, the maintenance of excitation and inhibition balance emerged as a key factor to regulate proper functioning of neuronal circuitry. Interestingly, our previous study involving the valproic acid animal model of autism (VPA animal model) has demonstrated excitatory-inhibitory imbalance (E/I imbalance) due to enhanced differentiation of glutamatergic neurons and reduced GABAergic neurons. Here, we investigated the potential of agmatine, an endogenous NMDA receptor antagonist, as a novel therapeutic candidate in ameliorating ASD symptoms by modulating E/I imbalance using the VPA animal model. We observed that a single treatment of agmatine rescued the impaired social behaviors as well as hyperactive and repetitive behaviors in the VPA animal model. We also observed that agmatine treatment rescued the overly activated ERK1/2 signaling in the prefrontal cortex and hippocampus of VPA animal models, possibly, by modulating over-excitability due to enhanced excitatory neural circuit. Taken together, our results have provided experimental evidence suggesting a possible therapeutic role of agmatine in ameliorating ASD-like symptoms in the VPA animal model of ASD.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2016.09.014

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 65 references

Cited by

Sorted by citations

Items 101–102 of 102

Related

See all

Metadata

Authors
Kim, J.-W., Seung, H., Kim, K. C., Gonzales, E. L. T., Oh, H. A., Yang, S. M., Ko, M. J., Han, S.-H., Banerjee, S., & Shin, C. Y.
Affiliations
  • Konkuk University (KR)
  • National Brain Research Centre (IN)
Corresponding author
Shin, Chan Young
ORCID
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2017-02
Volume
113
Issue
Pt A
Pages
71-81
ISSN
0028-3908 (ISSN-L)
DOI
10.1016/j.neuropharm.2016.09.014
OpenAlex
W2519436935
Cited by
102
References
65
Citations by year
2026: 3 · 2025: 13 · 2024: 13 · 2023: 8 · 2022: 14 · 2021: 10 · 2020: 11 · 2019: 11 · 2018: 13 · 2017: 6
FWCI
6.36
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Neuropharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Research Foundation of Korea
  • Korea government (2014R1A2A2A01003079, 2016R1A5A2012284)
  • Korea Health industry Development Institute
  • Ministry of Health & Welfare, Republic of Korea (HI12C0021)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
agmatine, autism spectrum disorder, excitatory-inhibitory imbalance, NMDA receptor antagonists, social behavior deficits, repetitive behavior, hyperactivity, ERK signaling, prefrontal cortex, hippocampus, glutamatergic neurons, GABAergic neurons, autism treatment
MeSH terms
Autism Spectrum Disorder, Agmatine, Animals, Disease Models, Animal, Grooming, Hippocampus, Hyperkinesis, Male, Mice, Transgenic, Neurons, Seizures, Social Behavior, Valproic Acid, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Prefrontal Cortex, MAP Kinase Signaling System, Mice, Rats, Neural Stem Cells, Primary Cell Culture

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review